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INTRODUCTION 
"Gentlemen, it is interesting to follow the stages in 
the recognition of a new disease. Very rarely does it 
happen that at all points the description is so complete 
as at once to gain universal acceptance". With these 
words Osier opened his famous "Clinical Lecture on Erythre­
mia", held at Radcliffe Infirmary, Oxford on November 28, 
1907 (Osier 1908). They truly characterized the stepwise 
emergence of a new hematologic entity, since the original 
description, 15 years earlier, of "une form spéciale de 
cyanose s'accompagnant d'hyperglobulie excessive et per­
sistante" by the French physician Vaquez (Vaquez 1892) . 
Since Osier's time careful clinical observations and a mul­
titude of experimental investigations have greatly expanded 
our knowledge of the disease we now call polycythemia vera 
(PV). But still today, 70 years later, we lack informa­
tion on many important points. Not even our present con­
cept of the natural course of the disease is "complete", 
but in essential respects controversial and far from "uni­
versal acceptance". 
Already in Osier's lecture the essential clinical featu­
res of PV were summarized. The patient he demonstrated, a 
54-year old woman, presented the classical "triad of symp­
toms": the face "had a dusky hue and the lips a purple 
tint", the spleen was greatly enlarged, and the red blood 
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corpuscles were 9.700,000/mm . He emphasized important 
symptoms such as headache, weakness, vertigo and prostra­
tion, and he was also able to separate this disorder from 
relative polycythemia caused by hemoconcentration and from 
secondary polycythemia, due to chronic anoxia. More ob­
scure was to him the etiology of the new disease, "the 
cause of the mysterious flooding of the body markets with 
the products of its red-blood factories". The problem of 
the nature of the hematopoietic proliferation in PV has 
ever since been under debate. It is still not solved today. 
During the decades following its description the concept 
of the disease was broadened. Turk (1904) called attention 
to the frequent occurrence of granulocytic leukocytosis 
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and the presence of immature red and white cells in the 
peripheral blood of patients with PV, supposed to be the 
results of an overactivity of the leukopoietic as well as 
the erythropoietic tissue. The associated megakaryocytic 
activity was first described by Hutchinson and Miller (1906). 
In the report by Minot and Buckman (1923) it was noted that 
some patients with long standing PV developed an anemia, 
that was supposed to be caused by increased leukoblastic 
and megakaryocytic activity of the marrow, depressing ery-
thropoiesis. That the PV disorder eventually could end up 
in a stage of marrow fibrosis and osteosclerosis was first 
shown by Hirsch (19 35). As a result of these and other 
studies it became evident that PV basically was a panmyelo­
sis, with a varying degree of proliferation of the diffe­
rent constituents of the marrow during different phases of 
the disease. 
The first rational approach to therapy in PV was phlebo­
tomy, reported beneficial as early as 1899 (Cabot 1899), 
and recommended by Osier "to relieve the fulness of the 
head" (Osier 1908). The method is still indispensable in 
PV therapy, and the only way to rapidly eliminate the risks 
of hypervolemia in a patient with newly discovered PV. For 
a considerable time the therapeutic modalities were other­
wise very limited and included such diverse prescriptions 
as sour milk (Weber 1908), oxygen inhalation (Osier 1908) , 
arsenic, benzol (Kiralyfi 1913), and Phenylhydrazine 
(Eppinger and Kloss 1918). Irradiation of the spleen was 
advocated already by Osier (1908) and later employed by 
others (Watson-Wemyss 1911). A more lasting hematologic 
remission was achieved when the irradiation was directed 
to parts of the skeleton containing hematopoietic marrow 
(Luedin 1920, Pack and Craver 1930). This mode of therapy 
was further improved with the use of spray irradiation 
(Richardson and Robbins 1948) . 
In 1940 Lawrence reported the use of radioactive phos­
phorus in the treatment of PV (Lawrence 1940) . Excellent 
results obtained in relief of symptoms and disappearance 
of abnormal physical signs were within short reported in 
large series of patients (Wiseman et al. 1951, Lawrence et 
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al. 1953, Wasserman 1954). The many advantages of P 
therapy made it rapidly popular and it can be supposed to 
still be the most used modality of treatment in PV. As 
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alternatives to Pa multitude of chemical agents have 
later been used to suppress the hyperactive polycythemic 
marrow. Pyrimethamine, a folic-acid antagonist, was among 
the first substances studied (Isaacs 1954), but it was 
soon surpassed by more potent myelosuppressive drugs, as 
they were shown to be able to control an abnormal cell 
proliferation in other hematologic disorders. Nitrogen 
mustard (Spurr et al. 1950), triethylene melamine (TEM) 
(Ellison et al. 1953), chlorambucil, cyclophosphamide, mel-
phalan, busulphan and other alkylating agents (Wald et al. 
1958, Killman and Cronkite 1961, Wasserman and Gilbert 
1966, Logue et al. 1970), were all demonstrated to be effec­
tive in the treatment of PV. 
The relationship between PV and other hematologic dis­
orders, particularly myelofibrosis with myeloid metaplasia 
and chronic granulocytic leukemia (CGL) was early discussed 
in the literature in connection with patients who presented 
features common to two or all of the disorders (Minot and 
Buckman 1923, Vaughan and Harrison 1939). In 1951 Dameshek 
proposed that these disorders, as well as megakaryocyte 
leukemia and erythroleukemia should be regarded under one 
heading as "myeloproliferative syndromes" (Dameshek 1951) . 
All reported cases of transitions between different myelo­
proliferative disorders were later critically reviewed by 
Glasser and Walker (1969), who concluded that while tran­
sitions definitely appeared to occur between PV and myelo­
fibrosis there was "no sound evidence that PV, myelofibro­
sis with myeloid metaplasia and CGL represents parts of a 
spectrum of a single disease". A similar conclusion was 
also reached by Ward and Block (1971), who emphasized the 
close relationship between PV and myelofibrosis (agnogenic 
myeloid metaplasia), characterized by a benign trilineage 
proliferation of hematopoietic cells, in contrast to the 
myeloleukemia conditions CGL and acute myeloid leukemia, 
characterized by a neoplastic proliferation of a single 
cell lineage. 
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Already in 1907 the supposed coexistance of PV and acute 
leukemia (AL) was described in the same patient (Blumenthal 
1907). The following years many reports of cases were pub­
lished, where PV and leukemia were thought to coexist or 
develop into each other. Altogether 83 such cases were re­
viewed by Schwartz and Ehrlich (1950), who found most of 
them inadequately documented. Thirty cases were, however, 
accepted as having both PV and AL. Almost all of these pa-
32 tients had received irradiation or P therapy. Only one 
unequivocal case of PV was found in which AL developed 
without previous irradiation. The authors suggested "that 
patients with PV who develop leukemia, develop it as a con­
sequence of previous irradiation therapy". Since this re-
32 port several large series of P treated patients have been 
published. With singular exceptions (Calabresi and Meyer 
1959, Hainan and Russell 1965) all of them have presented 
the development of AL in 10-20 % of the patients, e.g. 11% 
(Wasserman 1954), 21 % (Osgood 1965), 11 % (Modan and Lilien­
feld 1965), 20 % (Tubiana et al. 1968), 11 % (Lawrence et 
al. 1969) and 21 % (Rain et al. 1973). In contrast to 
these reports, indicating a causal relationship between 
32 irradiation and P therapy and the development of AL, 
Wasserman has repeatedly stated (Wasserman 1954, Wasserman 
and Bassen 1959, Wasserman 1976) that the "leukemia-like 
condition" occurring in PV is a natural terminal event in 
the course of the polycythemic disorder, unveiled through 
the prolongation of survival by more efficient therapy. 
"The development of leukemia in this disease is predestined 
from the very beginning. Although the course may be long, 
the original stimulus that created the disease is relent­
less and ultimately achieves its objective in all patients 
who survive long enough" (Wasserman and Bassen 1959). 
Thus widely differing opinions exist regarding the true 
nature of the PV disorder itself and of the relationship 
between PV and AL. Detailed comparisons of the findings 
in various reported series of patients with PV, treated one 
way or the other, are almost always impossible because of 
unspecified diagnostic criteria for the PV and the AL dia­
gnoses, different degrees of selection of the cases and un-
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even composition of the materials. In an attempt to bring 
this problem to a final solution the Polycythemia Vera Study 
Group (PVSG) was initiated and started its work in 1967 
(Wasserman 1971). Today about 450 patients with strictly 
defined PV from US, France and Sweden have been accepted in 
this study, randomized to three types of treatment (phlebo-
3 2 tomy alone, chlorambucil and P), and are meticulously 
followed up. It can only be hoped that at least some of 
the questions regarding the leukemogenesis in PV will be 
answered by this ambitious cooperative effort. 
Since more than ten years patients with PV and other mye­
loproliferative disorders have been followed with special 
interest in our clinic (since 1971 at the Section of Oncolo­
gical Haematology; Chief, A. Weinfeld). The ambition has 
been to study carefully the natural course of these diseases 
and to investigate clinically and experimentally different 
pathophysiologic and morphologic aspects of the myeloproli­
ferative process. The studies included in this thesis are 
all parts of such a more extensive and continuous research 
programme, going on in patients with PV and allied diseases. 
The main objects of the present investigations were: 
1) to prospectively study the bone marrow chromosomes 
in a consecutive series of PV patients during the natural 
course of the disease, with special regard to given modes 
of therapy and to the development of acute leukemia; 
2) to examine the size of the spleen with scintigraphic 
technique in PV during different phases of the disease, and 
in other polycythemias; 
3) to study the histamine metabolism in PV with special 
regard to other manifestations of the myeloproliferative 
process and to "histamine-related symptoms", and to compare 
with the findings in other polycythemias; 
4) to follow and describe the clinical, morphologic 
and cytogenetic features of the terminal acute leukemia in 
PV. 
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GENERAL CHARACTERISTICS OF PV PATIENTS 
SEEN IN GÖTEBORG 1965-1975. 
The incidence of PV in Göteborg and the manifestations 
of disease at the time of the clinical presentation has 
recently been examined in a retrospective study of all 
patients with polycythemia, treated at Sahlgren's Hospital 
during the years 1965 to 1975 inclusive. This material 
will be reported separately (Weinfeld and Westin 1976), 
but preliminary data from the study will be given here, in 
order to characterize some general aspects of the poly­
cythemic disorder in the PV patients. A diagnosis of PV 
was accepted in 89 patients. , Of these 71 were living in 
Göteborg, while 18 were admitted from the county hospitals 
in the surrounding region. The latter patients were not 
selected for referral because of special diagnostic or 
therapeutic difficulties, but were sent for an initial eva­
luation since we had announced an interest for myeloproli­
ferative disorders. When "regional cases" were compared 
with cases from Göteborg no significant differences were 
found. In the following description of the material all 
89 patients are considered together, but when incidence 
is discussed, only cases from Göteborg are taken into 
account. 
Incidence. During the 11 years 1965 through 1975 71 
cases of PV were diagnosed among the inhabitants of Göte­
borg. The average population during this period was 
450,000. The annual incidence of PV in Göteborg can thus 
be estimated to 14.3 cases per million. For several rea­
sons this figure must be regarded as a minimum incidence: 
1) Some cases with PV may have avoided detection. 2) At 
least five patients were registered under the diagnosis 
pf PV (208.99) but did not fulfill the diagnostic criteria. 
These cases may actually have had PV. 3) Not all case 
records from some clinics outside Sahlgren's hospital have 
as yet been examined in full detail. 
Age at diagnosis. The age at the time of diagnosis is 
shown in Fig. 1. "Cases from Göteborg" are separated from 
"regional cases". As can be seen the latter were evenly 
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AGE AT DIAGNOSIS 
• Cases from Göteborg 
S Regional cases 
90 years 
Figure 1. Age at diagnosis for 89 patients with PV. 
distributed in the material. The mean age was for men 60 
years, for women 61 years. Two patients were at the time 
of diagnosis very young (age 19 and 20). 
Clinical presentation. The interval from "time of on­
set" (defined as the earliest date at which symptoms or 
signs or laboratory findings, attributable to the PV, were 
noted) to "time of diagnosis" was in most patients very 
short, in 30 % less than one month, in 48 % less than three 
months. Only in 11 patients (= 12 %) the interval between 
symptoms or laboratory signs of PV and diagnosis was more 
than two years. The patients were divided in three groups 
according to the mode of clinical presentation, as shown 
in Table I: 1) PV accidentally discovered at a routine 
examination (16 patients = 18 %); 2) PV discovered when 
the patient was examined for an illness, not related to 
the PV (31 patients = 35 %); and 3) PV discovered because 
of "PV symptoms" (42 patients =47 %) . The main feature 
of the PV disorder that first attracted attention in the 
accidentally discovered patients was a high Hb or Hct 
value. The most frequent presenting symptom in group 3) 
was hemorrhage (hematemesis, melena, epistaxis, hematuria, 
retroperitoneal hematoma., bleeding after tooth extraction, 
easy bruisability) . 
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Table I. Mode of clinical presentation for 89 patients with PV. 
Main feature(s) first 
attracting attention 
Patients in 
each group 
n % 
1. Discovered Increased Hb or Hct 16 > 
accidentally- Thrombocytosis 2 ^ 16 18 
Splenomegaly 1 y r 
2. Discovered when Increased Hb or Hct 24 > 
examined for Thrombocytosis 9 
other illness Leuköcytos is 7 >. 31 35 
Splenomegaly 3 
: 
Hyperkalemia 3 J 
3. Discovered Hemorrhage 15 > 
because of PV Thrombosis 4 
symptoms Myocardial infarction 1 
Cerebrovasc. accident 3 
Peripheral circulatory 
disturbance 3 
Abdominal mass (spleen) 3 >• 42 47 
Pruritus 2 
Vertigo 4 
Amaurosis fugax 1 
General symptoms 1 
Epileptic fits 1 
Hemorrhoids 3 
Hematocrit. The hematocrit at the time of the first 
examination is presented in Fig. 2. The mean hematocrit 
was for men 62 and for women 60 
HEMATOCRIT 
N 
20 
10-
Figure 2. Hematocrit 
at the time of diagnosis 
for 89 patients with PV. 
48 52 56 60 64 68 72 O/ 76 80 % 
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N 
20 
15-
RED BLOOD CELL MASS 
H 
• Men 
EH Women 
32 40 48 56 64 72 80 ml/kg b.wt. 
Figure 3. Red blood cell 
mass, measured with ^Cr, 
at the time of diagnosis 
for 43 men and 41 women 
with PV. 
Red blood cell (RBC) mass. The initial RBC mass was 
51 
measured with Cr in 84 patients. The results are shown 
in Fig. 3. For 2 8 men and 3 3 women without previous blood 
loss the mean RBC mass was 56 and 48 ml/kg b.wt. respecti­
vely. For 15 men and eight women, who had bled or been 
phlebotomized before determination of the blood volume, 
the mean value was 51 and 39 ml/kg b.wt. respectively. 
Splenomegaly. Forty patients (= 45 %) had a palpable 
spleen at the initial examination. When more accurate 
methods were employed the proportion of cases with spleno­
megaly increased. As shown in Fig. 4 this proportion was 
62 % for patients examined with a plain X-ray of the ab-
SPLENOMEGALY 
N 
80-
60-
40H 
20-
Palpation X-ray 
O Not examined 
D No splenomegaly 
[3 Splenomegaly 
Scintigraphy 
Figure 4. Proportion of PV 
patients with splenomegaly at 
the time of diagnosis, as judged 
by palpation, plain X-ray of 
the abdomen and 
graphy. 
99m' Tc scinti-
13 
20, 
10-
WHITE BLOOD COUNT 
Figure 5. White blood 
count at the time of dia­
gnosis in 89 patients with 
PV. 
4 8 12 16 20 »20 -103 cells/pl 
PLATELET COUNT 
N 
20-, Figure 6. Platelet count 
at the time of diagnosis 
in 89 patients with PV. 
• • 
200 400 600 800 1000 >«°° -103cells/yl 
LEUKOCYTE ALKALINE PHOSPHATASE 
N 
15n 
Figure 7. LAP score in 67 
patients with PV, examined 
at the time of diagnosis. 
5-
100 
:j=i=j 
300 score 
domen (lower limit for "roentgenologic splenomegaly" 16.5 
Q 9m 
cm), and 70 % for patients studied with Tc scintigraphy 
(lower limit for "scintigraphic splenomegaly" 290 ml, cf. 
p. 33). 
White blood count. The initial white blood count is 
shown in Fig. 5. In 47 % of the patients a leukocytosis 
( >12 , 000/pl ) was found, but only nine cases had values 
above 20,000/pl. The mean white blood count was 12,700/ul. 
Platelet count. The initial platelet count is presen­
ted in Fig. 6. A platelet count above 400,000/pl was ob­
served in 46 % of the cases. Two patients had values 
above 1. 000 , 000/pl. The mean platelet count was 422 , 000/jil. 
Leukocyte alkaline phosphatase (LAP). The LAP activity 
was examined in 67 cases. The result is presented in Fig. 
7. Scores above 100 were obtained in 51 patients (= 76 %). 
The mean LAP score was 154. 
Survival. The expected survival of patients with PV 
from the time of diagnosis was estimated according to the 
life-table method, and compared to the expected survival 
of age-matched individuals from the general population. 
The results are shown in Fig. 8. For this comparison all 
PV patients were considered together, independent of what 
type of therapy had been administered (phlebotomy alone, 
3 2 P, chemotherapy with alkylating drugs or combinations 
of several modalities). For patients with PV the probabi­
lity of surviving more than five years was 75 %, and more 
than ten years 57 •%. For the age-matched controls the 
probability to survive the corresponding periods of time 
was 87 and 72 % respectively. The difference in expected 
survival between PV patients and controls was significant. 
However, when the expected survival was analysed for men 
and women separately, the difference between men with PV 
and male controls was not significant, while women with 
PV showed a significantly shorter expected survival than 
female controls. When patients with and without leukocy­
tosis were compared a nearly significant difference was 
found (0.05>p<0.10), indicating that a high white blood 
15 
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X 
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8 9 10 6 3 5 7 4 2 1 
YEARS FROM DIAGNOSIS 
Figure 8. Expected survival from the time of diagnosis for 89 
patients with PV, compared with the expected survival in an age-
and sex-matched control group from the general population. 
count at the initial evaluation may be a bad prognostic 
sign. 
Comments. The incidence of PV has been studied in de­
tail only in a few reports, all from USA. Modan (1965) 
examined the incidence of PV in Baltimore 1951-1960 and 
found a minimum annual incidence rate of four to five new 
cases per million. A similar figure was given by Goin 
(1973), who estimated the annual incidence rate in Oklahoma 
City 1965-1971 to 3.5 per million. Silverstein and Lanier 
(19 71) on the other hand, who studied the incidence of PV 
in Rochester, Minnesota 1935-1969 found a much higher in­
cidence of 16 cases per million per year. This study was 
based on the very careful diagnostic indexing system of 
the Mayo Clinic, and can be supposed to reflect a high 
level of case discovery. The average annual incidence of 
PV in Sweden, calculated from the reports to the Swedish 
Cancer Registry was for the years 1965 to 1970 12.5 cases 
per million. 
The mean age in the Göteborg series of PV patients was 
16 
the same as in the PVSG material reported by Berlin (1975). 
When compared to other published series of PV the propor­
tion of cases with accidentally diagnosed disease was very 
high in the present material. Figures for this mode of 
detection have been given as 11 % (Calabresi and Meyer 
1959), 10 % (Chievitz and Thiede 1962) and 17 % (Perkins 
et al. 1964). In our series PV was suspected at a routine 
examination in 18 % and incidentally when the patient was 
examined for another illness in a further 35 %. Figures 
like these may indicate that in this country most patients 
with PV are discovered very early in the course of their 
disease. 
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MATERIAL 
The criteria for the diagnosis of PV are reported in 
Paper III and are almost identical to those established 
by the PVSG (Wasserman 1971) . 
Untreated PV. With "untreated PV" is meant that no 
32 irradiation, P or alkylating drug therapy had been given. 
In some "untreated" cases therapeutic phlebotomies had, 
however, been done one or several times before the diffe­
rent investigations. The studies reported in this thesis 
were mainly done on patients belonging to a series of con­
secutive cases of newly diagnosed PV, observed in our cli­
nic since 1969. Scintigraphic studies were done on 57, 
histamine studies on 27 and cytogenetic studies on 50 un­
treated patients. 
PV in remission. Remission is defined as a state of 
3 2 haematopoietic suppression, achieved with P or alkyla­
ting drugs. All patients in remission remained on Hct 
levels less than 50 % without the aid of phlebotomies, and 
did not rise in Hct after iron administration. All had a 
normal peripheral white and platelet count and no symptoms 
referable to PV. Scintigraphic studies were done on 17 
and histamine studies on 15 patients in remission. 
PV in relapse. Relapse is defined as a state of active 
disease in a patient previously treated with myelosuppres-
sive agents, who had either not responded to therapy or had 
for some time been in remission. Patients in relapse should 
fulfill the diagnostic criteria for PV described above. 
Scintigraphic studies were done on 11 and histamine studies 
on 8 patients in relapse. 
Active PV. Patients with untreated PV and PV in relapse 
are in some of the studies considered together as "active 
PV" . 
Other forms of absolute polycythemia. An absolute poly­
cythemia is by definition present in all patients with a 
RBC mass>36 ml/kg b.wt. in men and>32 ml/kg b.wt. in wo­
men. The patients included in this group had no spleno-
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megaly and no signs of the panmyelosis typical of PV. Some 
of the patients in this group had secondary polycythemia, 
(four with cardiac malformations and right-to-left shunts, 
three with renal polycythemia and one with polycythemia 
secondary to a uterine fibroid). In the remaining patients 
no obvious reason for the increased erythropoietic activity 
could be demonstrated in spite of careful investigation. 
It is not impossible that some patients in this group 
suffered from early PV. Neither can it be excluded that 
some cases had a polycythemia, secondary to a defective 
oxygen transport (Weatherall 1969, Adamson 1975). However, 
most of the patients in this group had the clinical and 
laboratory features of "benign erythrocytosis" (Russell and 
Conley 1964, Modan and Modan 1968) . Scintigraphic studies 
were done on 16, histamine studies on 10 and cytogenetic 
studies on 10 patients with absolute polycythemias other 
than PV. 
Pseudopolycythemia. The term pceudopolycythemia is used 
for patients with persistently elevated Hct values (>52 %) , 
but with a RBC mass within the normal limits. Many of 
these cases can be considered as normal variants with a low 
normal plasma volume and a high normal RBC mass (Brown et 
al. 1971) . Others, who have a consistently decreased plas­
ma volume, may have a true clinical disease (Weinreb and 
Shih 1975). Scintigraphic studies were done on 32, hista­
mine studies on 5 and chromosome studies on 5 patients with 
pseudopolycythemia. 
GENERAL METHODS 
Peripheral blood values were in the experimental studies 
determined on venous blood collected in EDTA tubes. Hemo­
globin was determined as cyanmethemoglobin. The hematocrits 
were measured in an International microhematocrit centri­
fuge at a speed of 11,500 rpm for 5 minutes. The blood 
cells were counted in a Coulter Counter, Model F. 
Leukocyte alkaline phosphatase (LAP) was assayed cyto-
chemically according to Kaplow (1955). 
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Blood volume. The RBC mass was measured by an isotope 
dilution technique using 51Cr according to the method of 
131 Sterling (1960) . Plasma volume was measured by the J-
labelled human serum albumin method. Total blood volume 
51 is given as the RBC mass, measured with Cr, plus the 
131 plasma volume, measured with J. 
Bone marrow. Core biopsies for histological examina­
tion were obtained with a Radner needle from a lumbar 
spinous process. The material was examined according to 
the principles described by Lundin et al. (1972). The 
cellularity was given as %; the amount of megakaryocytes 
was graded as decreased (-), normal (N), slightly (1+), 
moderately (2+), and markedly (3+) increased; the reticu-
lin content of the marrow was estimated in sections 
stained according to Laidlow and graded as normal (N), 
slightly (1+), moderately (2+), markedly (3+) increased, 
and as markedly increased in combination with collagen 
formation (4+). 
Statistical methods. Standard statistical methods were 
used for calculation of mean values, standard deviation 
(SD), standard error of the mean (SEM) and linear regres­
sion (Snedecor 1959). Unless otherwise stated mean value 
- SD is reported. The standard error of a single determi­
nation was calculated from duplicate measurements on the 
same sample according to the formula \JXd^/2n (Dahlberg 
1948). Mean values were tested according to the t-test 
when no difference of variances was present according to 
the F-test (Snedecor 1959). When the variances were 
different a t-test was used with adjustment of the degrees 
of freedom according to Welch (1949). The difference of 
means was considered statistically significant if p<0.05. 
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CHROMOSOME STUDIES 
Methods. The bone marrow chromosomes were studied in 
direct preparations according to the general principles 
described by Tjio and Whang (1962), with minor modifica­
tions. Until 1974 all slides were stained with conventional 
orcein or Giemsa, thereafter the technique for G-banding 
described by Wang and Fedoroff (1972) was used with slight 
modifications. Bone marrow and peripheral blood prepara­
tions from patients with abnormal cell lines were also 
studied in Q-banded preparations according to Caspersson 
et al. (1970). 
After conventional staining or G-banding the slides were 
studied in a Zeiss Photomicroscope with a 25x screening 
optic and a lOOx Neo-Fluar oil-immersion optic for detailed 
analysis and photography. As a rule 30-50 cells were coun­
ted and if possible karyotyped. A number of representative 
cells and cells with numerical and structural abnormalities 
were photographed for karyotyping from photographic en-
largings. Slides intended for Q-banding were first studied 
with phase-contrast in the same type of microscope in order 
to select a number of suitable metaphases for photography. 
After banding and fluorescent light photography the selec­
ted cells were karyotyped from photographic enlargings. 
Comments on methods. It is difficult to produce techni­
cally good preparations of bone marrow chromosomes in gene­
ral, and of PV chromosomes in particular. Very often the 
number of mitoses is low, the proportion of analysable 
metaphases is low, and the general quality of both analysab­
le metaphases and individual chromosomes is low. Care and 
experience during the preparation procedure and a great 
patience at the microscope are essentials for a good result. 
When interpreting the microscopic findings in preparations 
of bone marrow chromosomes certain facts should be born in 
mind: 
1) artefacts may be induced during the preparation pro­
cedure. Metaphases may be split up and one or more chromo­
somes lost or gained; 
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2) the technical quality (the "analysability") of the 
metaphases may vary between different cell populations in 
the same patient. It is well known that the chromatin e.g. 
in acute leukemia often has an ill-defined and blurred 
character. If different clones of cells are present in 
the marrow of PV patients it is possible that the cells 
belonging to the pathologic clone consistently give rise 
to metaphases, less well suited for analysis; 
3) a serious bias can be introduced during the micro­
scopic examination, if not all metaphase spreads (irrespec­
tive of quality) are given equal attention. All metaphases 
must be studied, and an analysis always attempted when the 
number of the chromosomes can be counted, and no obvious 
artefacts are present. 
Good results with the new banding methods require chro­
mosome preparations of a higher quality than when conven­
tional staining is used. Contracted or clumsy chromosomes 
or chromosomes with fuzzy chromatin give an indistinct 
banding pattern and are very difficult to evaluate. The 
methods of banding used in this study essentially deliver 
the same information, but often supplement each other. In 
certain respectsthe G-banding method is easier to handle, 
the most obvious advantage being that the chromosome pre­
parations without hurry can be studied with high magnifica­
tion and oil-immersion optics. It is quite evident that 
the banding methods give much more information of the 
chromosome constitution than convetional staining. Some 
of the structural abnormalities observed in the present 
studied might not have been discovered without banding 
(e.g. the deleted no. 12 in patients I.H. and H.G., simula­
ting a normal D group chromosome). 
Results. Chromosome studies were carried out in patients 
with PV during three different phases of the polycythemic 
disorder: 1) at the time of the initial evaluation, be­
fore any myelosuppressive therapy (50 patients, Paper I); 
2) 1-4 years after the initial study, still in the poly­
cythemic phase, with or without myelosuppressive therapy 
(27 patients, Papers I, II and V); 3) at the time of the 
leukemic transformation (6 patients, Paper V). 
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Already at the time of the PV diagnosis seven patients 
(= 14 %) had an abnormal cell line established in the bone 
marrow, in four cases dominating over cells with a normal 
karyotype. Three abnormal cell lines contained each two 
additional C group chromosomes (in all cases identified as 
no. 8 and no. 9). Two patients carried in all cells an 
additional B or C size marker chromosome, where most of 
the material in the long arms was derived from chromosome 
no. 1. One patient had an additional unidentified iso-
chromosome, and one a consistent loss of chromosome no. 16. 
A singular hyperdiploid cell was present in each of six 
patients (Paper I). 
Of the 50 patients initially studied, 29 have been exa­
mined a second time, 1-4 years after the first examination. 
Twenty-seven eases were still in the polycythemic phase, 
two in leukemic transformation. Between the two studies 
12 patients were treated with phlebotomies alone, eight 
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with chlorambucil and nine with P. In 24 patients the 
follow-up studies showed the same normal or abnormal karyo­
type as in the first study. In three patients a normal 
karyotype was replaced by an abnormal cell line, in two 
patients additional abnormalities were observed in a marrow, 
already abnormal at the first study: 
1) A.O., normal in the first study, developed a balan­
ced translocation, t(l;5), in all cells after 40 months of 
chlorambucil therapy (Paper II); 
2) I.H., normal in the initial study, during therapy 
with chlorambucil first developed a deletion of chromosome 
no. 12 (12p-) in most but not all cells. When studied one 
year later the same abnormality was present in all cells, 
and in addition a deletion of chromosome no. 20 (20q-) in 
3 of 38 cells (Paper II); 
3) E.O. had in the initial study an additional marker 
(lp-?) and a deletion of no. 20 (20q-) present in all 
cells. After 3 years of treatment with phlebotomies alone 
4 cells with the 20q- deletion contained an extra no. 9, 
but no marker (Paper I); 
4) E.H., who carries a pathological cell line with the 
karyotype 48,XY,+8,+9, in the last study (October 1975) 
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presented a single cell with the typical deletion of 
chromosome no. 20 (20q~); 
5) M.B., initially normal, after 3 years of chlorambu­
cil therapy developed a leukemic transformation. Studied 
in close connection to the diagnosis of the leukemia the 
marrow contained two cell lines, one with the deletion of 
no. 20 (2Oq—) as the sole abnormality, one with the karyo­
type 46,XO,+mar (marker unidentified) (Paper V) . 
Altogether six patients were examined in the leukemic 
phase of their PV. In two of them initial chromosome stu­
dies had been done. One patient was normal initially and 
normal when leukemic. The features of the second patient 
studied initially (M.B.) were described above. In one 
patient all metaphases were hypotetraploid with a chromo­
some number between 57 and 88. The marrow of the remaining 
three patients all contained multiple numerical and/or 
structural abnormalities, indicating the presence of seve­
ral pathological cell lines (Paper V). 
In Table II are summarized all main chromosome abnorma­
lities observed in PV patients in our laboratory between 
1969 and 1975. Besides the abnormalities presented in 
Paper I, II and V pathological cell lines from two further 
patients are included in the table. Both had a disease of 
32 long standing and had been treated with P and alkylating 
drugs during many years. One patient (M.N.) had three 
abnormal cell lines: a) 47,XX,+8; b) 47,XX,+8,2 0q-; 
c) 46,XX,-3,-5,+8,+mar(2q+?). The other patient (K.P.) 
had two abnormal cell lines: a) 46,XY,t(9 ; 17) ; 
b) 46,XY,20q-. It seems obvious from the present studies 
that in PV some chromosomes definitely are more often in­
volved (supernumerary, lost, structurally rearranged) than 
the others (no. 1, 8, 9, 12, 20). All supernumerary nor­
mal chromosomes were no. 8 and/or no. 9. The most frequent 
structural abnormality was the deletion of chromosome no. 
20 (20q-), observed altogether in six patients. In three 
patients structural rearrangements of chromosome no. 1 were 
present, in two of them as a trisomy for the long arm of no. 
1. Two patients presented a possibly identical deletion of 
chromosome no. 12 (12p—) . 
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Table II. Main chromosome abnormalities observed in patients with PV. 
Chromosome 
no. 
Consistent Consistent 
additions losses 
Structural 
rearrangement s 
1 -Hp- (?) > +1( 1 ;9),t(1 ;5) 
2 t(2;13),t(2;?) 
3 -3 
4 4q-
5 
A 
-5 t ( 1 ; 5 ) 
u 
7 
8 +8,+8,+8,+8,+8,+8 
9 +9,+9,+9,+9,+9,+9,+9 +t(l;9),t(9;17) 
10 
11 -11 
12 12p-,+12p-,+12p-
13 t(2;13),t(13;?) 
14 
15 -15 
16 -16 
17 t(9;17) 
18 
19 
20 
21 
20q-,20q-,20q-,20q-, 
20q-,20q-
22 
XY -X 
Each figure (e.g. +8 or 4q~)denotes one abnormality in one patient. 
Bone marrow chromosomes in other forms of absolute poly­
cythemia and in pseudopolycythemia. Chromosome studies 
were performed as part of the diagnostic work-up in 16 
patients (14 men, 2 women) referred with a clinical suspi­
cion of PV. The final diagnoses of these patients were: 
polycythemia secondary to a uterine fibroid (1 case), 
"benign erythrocytosis" (10 cases), and pseudopolycythemia 
(5 cases). Fifteen patients had normal karyotypes. One 
patient (J.M.) with a very active erythrocytosis of unknown 
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origin, had 22 % hypodiploid cells (6 of 11 missing chro­
mosomes were no. 19 and/or no. 20), and 12 % polyploid 
cells. One or several hypodiploid cells with an apparently 
random loss of chromosomes were found in 13 of 16 patients 
(= 81 %). The random losses seemed to occur more often in 
chromosome groups E, F and GY. Polyploid cells were ob­
served in 5 of 16 patients (= 31 %). A singular hyperdi-
ploid metaphase was found in one patient. 
Discussion. When a pathological cell clone dominates in 
the bone marrow it is easily detected, and provided the 
quality of the banding is good the abnormality can usually 
be defined. However, if a minor clone of cells is to be 
observed some conditions must be fulfilled: 1) the cells 
in the pathological clone must divide; 2) the abnormality 
in the pathological cells must be large enough to be de­
tected; 3) the cells in the clone must be numerous enough 
to have a chance to appear among the 50 analysed cells. 
In the present studies we arbitrarity considered a patho­
logical cell line to be present when at least 10 % of the 
studied cells had an identical abnormality (minimum 5 
cells), in order to guarantee the exclusion of findings 
with a questionable significance. A similar definition 
was used by Wurster-Hill et al. (1976). With these rather 
narrow criteria some patients with small abnormal clones 
presumably will not be correctly classified. A minor cell 
line may also be overlooked when only 50 cells are analysed. 
The number of abnormal clones found in our patients with 
untreated PV should therefore be considered as a minimum. 
The interpretation of minor abnormalities, specially 
varying degrees of aneuploidy, is even more difficult. A 
few series of bone marrow chromosome studies in control 
subjects are reported, but not all of them are comparable 
to the PV patients in age, sex and other respects (Sandberg 
et al. 1961, O'Riordan et al. 1970, Secker-Walker 1971, 
Pierre 1974). In our PV patients studied initially 84 % 
had hypodiploid cells, constituting 8 % of all metaphases 
analysed. In the small group with erythrocytosis and 
pseudopolycythemia the figures were almost identical: 
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81 % (patients with hypodiploid cells) and 8 % (hypodiploid 
metaphases). This degree of aneuploidy -is in the same 
range as was found in the cited series of normal controls. 
A certain pattern seems to emerge from the chromosome 
studies in PV, indicating a susceptibility of certain 
chromosomes (1, 8, 9, 12, 20) to be more frequently invol­
ved than others in aneuploid or structurally rearranged 
karyotypes (Table II). The deletion of the long arms of 
chromosome no. 20 (20q-) seems however to be the only ab­
normality characteristic for PV patients (Millard et al. 
1968, Reeves et al. 1972, Shiraishi et al. 1975) . The only 
exceptions to this rule are some patients with sideroblastic 
anemia reported by DeGrouchy et al. (1966). In the selec-
32 ted material of mainly P treated patients from Radium­
hemmet this deletion was observed in 8 of 50 cases (Vis-
feldt et al. 1973), and in the hitherto published material 
from Royal Marsden Hospital in 15 of 79 cases (Lawler et 
al. 1970). In some patients the deletion is present al­
ready at the clinical presentation of the PV, in other 
patients it develops during the course of the disease. If 
this is an effect of therapy or a feature of the myelopro­
liferative process itself cannot as yet be decided. Varia-
Figure 9. Chromosome pair no. 20 from six patients with PV, examined 
with G-banding (upper row) and/or Q-banding (lower row). One chromoso­
me in each pair is normal, one shows a deletion of the long arms, 
del(20)(qll). In patients E.O. and E.H. the chromosome studies were 
done before active therapy, in patient M.B. after chlorambucil therapy 
when she was in leukemic transformation, in the remaining patients 
after various periods of therapy with P (K.P.) chlorambucil (I.H.) 
and 32p plus several alkylating drugs (M.N.) 
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tions in length of the 20q- deletion have earlier been re­
ported (Visfeldt 1971), but in our patients all seemed to 
have the "typical" break in the qll region (Shiraishi et 
al. 1975) (Fig. 9). 
All but one of the patients studied during the leukemic 
phase presented numerous and complex chromosome abnormali­
ties, often as several abnormal cell lines with superim­
posed aberrations, presumably reflecting a clonal evolu­
tion. One of the characteristics of a clonal evolution, 
the tendency to duplicate supernumerary chromosomes 
(Lejeune 1965, DeGrouchy and Turleau 1974) was observed in 
two of the patients (duplication of a supernumerary no. 9 
in patient T.L. and of a deleted additional no. 12 in 
patient H.G.; Paper V). Almost all reported patients in 
leukemic transformation of PV have had similar advanced 
abnormalities (9 of 9 patients in Lawler et al. 1970, 5 of 
8 in Visfeldt et al. 1973). One of the patients had during 
the leukemic phase only "polyploid" (hypotetraploid) cells 
in the marrow, a finding earlier reported in singular 
patients with acute leukemia (Trujillo et al. 1971). 
28 
SPLEEN SIZE 
Method. The spleen size was determined scintigraphi-
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cally with Tc sulphur colloid and a gamma camera tech­
nique. Details of the method are described in Paper III. 
Except for a slight modification in the colloid prepara­
tion the original method has been unchanged. The camera 
now in use is a Nuclear Chicago Pho-Gamma III HP, equipped 
with a 13-inch crystal and a 15,000-hole collimator, 
giving an improved resolution in the gamma camera image 
compared to the older instrument. With 5mCi of the colloid 
injected the radiation to the patient can be estimated to 
0.1 rad in whole body dose and 0.8 - 2.0 rad in spleen 
dose (Smith 1965). In routine work the size of the spleen 
is reported as "lateral and posterior spleen area", measu­
red from the lateral and posterior gamma camera images, 
according to the principles described in Paper III. When 
spleen scintigraphy was used in clinical and experimental 
studies the size of the spleen has been expressed as 
"spleen volume", calculated according to the formula 
V = 0.3\la3 (V = volume, a = largest spleen scan area), as 
suggested by Fischer (1970). 
Comments on method. The most obvious advantage with a 
scintigraphic technique for spleen size determination is 
that the spleen is always visualized. With palpation and 
with a plain X-ray of the abdomen many slightly enlarged 
spleens pass unnoticed. Sometimes even a gross splenome­
galy may avoid detection (Riemenschneider et al. 1965, 
Blendis et al. 1970). Except in asplenic individuals there 
is only one condition, in which the spleen cannot be visua­
lized with isotopic methods, i.e. when the splenic artery 
is thrombosed, causing a "functional asplenia" (Marsh et 
al. 1966). This complication was presumably present in 
one of our PV patients, a 61-year old woman with Hct 60 % 
and platelets 1. 200, 000/fjl, who had no uptake in the 
spleen scan and signs of splenic atrophy (Howell-Jolly 
bodies, target cells) in the peripheral blood. 
In most gamma camera images the size of the spleen can 
easily be measured, but the method has certain limitations: 
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1) very large spleens cannot be measured accurately, 
partly because the size of the collimator is a limiting 
factor, and partly because the lateral scan area only is 
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representative of the actual spleen size up to 200-220 cm 
(volumes of 800-1000 ml). In normal-sized organs either 
the lateral or the posterior scan area can be used for the 
calculations, and in cases of moderate splenomegaly the 
lateral scan area most obviously reflects the increase in 
size. A gross enlargement of the spleen, on the other 
hand,mainly announces itself in the anterior projection, 
which is less suitable for scintigraphic measurements; 
2) the areas of liver and spleen activity may be diffi­
cult to separate in the lateral projection. This is a 
disadvantage of all techniques, using a colloid that accu­
mulates in both liver and spleen, in contrast to more 
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selective methods using Cr- or Tc-labelled heat-dena­
tured erythrocytes. At least in moderately enlarge spleens 
an anterior oblique projection can make it easier to define 
the spleen area; 
3) infarctions in the spleen may complicate the calcu­
lations through deformations of the spleen contour or areas 
of decreased intensity. 
The main difficulty in measuring the spleen area lies 
in definition of the line, enveloping the area of activity 
in the polaroid film of the gamma camera image. The basis 
for the calculations on the film was evaluated with phantom 
studies, as described in Paper III. Duplicate measurements 
gave a very low coefficient of varation (3 %). Several 
authors have devised formulas for calculation of the spleen 
volume from measurements made on the spleen scan (Spencer 
1967, Samuels 1969, Fischer 1970, Rollo and DeLand 1970, 
Larson et al. 1970). The theoretical background for these 
calculations was discussed by von Behrens (1973), who con­
cluded that the formula V = 0.3 \J a3 (V = spleen volume, 
a = spleen scan area), originally proposed by Spencer 
(1967), and later modified by Fischer (1970), was well 
applicable in clinical practice. Recently the problems of 
spleen volume calculations were critically investigated by 
Aito (1974). He also found this formula well suited for 
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calculation of the spleen volume from measurements of the 
area in the gamma camera image. A slight adjustment of 
the proportionality factor to 0.33 gave in his phantom 
studies a better correlation to the actual volume. 
The relationship between the calculated spleen volume 
and the actual spleen weight at splenectomy was examined 
in 35 scintigraphically studied patients with various dia­
gnoses (Hodgkin and non-Hodgkin lymphoma, idiopathic throm­
bocytopenic purpura, haemolytic anemia, CGL). Only spleens 
weighing less than 800 g were included. The interval be­
tween scintigraphy and splenectomy was in 28 patients less 
than four weeks, in seven patients 5-20 weeks. Cytostatic 
therapy or irradiation was not given to any patient between 
the examinations. As shown in Fig. 10 a highly significant 
correlation was found between calculated spleen volume and 
actual spleen weight (r = 0.96). When also volumes of 
O 
larger spleens, calculated from scan areas above 200 cm 
were included in the material the correlation was still 
significant, but with increasing degree of splenomegaly 
the underestimation of the actual spleen weight became 
more marked. 
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Figure 10. The relationship between calculated spleen volume and 
actual spleen weight at splenectomy in 35 patients with various dia­
gnoses. The thick line marks the regression line (r = 0.96), the 
thin line represents the identity line. 
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Results. The accumulated results from an enlarged 
series of patients studied with spleen scintigraphy in this 
clinic since 1969 are presented in Fig. 11. The material 
consists of 57 patients with untreated PV, 23 with other 
forms of absolute polycythemia, and 32 with pseudopoly-
cythemia. Included in the figure are also the 22 original 
control subjects. 
Untreated Other forms Pseudo- Controls 
polycythemia of absolute polycythemia 
vera polycythemia 
Figure 11. Calculated spleen volume in patients with untreated PV, 
other forms of absolute polycythemia, pseudopolycythemia and in control 
subjects. In the group with untreated PV the horizontal line marks 
the mean value. In the other groups the lines represent the mean 
value - 2 SD. 
The mean value of the spleen volume in the control group 
+ + 
was 140 - 20 ml. The mean - 2 SD is considered as the nor­
mal range (60-220 ml). In absolute polycythemias other 
than PV the mean value was 170 - 60 ml, and in pseudopoly­
cythemia it was 160 - 50 ml. A significant difference was 
found between the mean values for controls and patients 
with other forms of absolute polycythemia, but there was 
no difference between the mean values for controls and 
patients with pseudopolycythemia. 
The series of 57 untreated PV patients reported here con­
sists of all cases diagnosed in this clinic since 1969. The 
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mean value of the spleen volume was 520 ml, with a large 
standard deviation (340 ml), median value 400 ml, range 
140-1,630 ml. In most patients the enlargement of the 
spleen was slight to moderate. A very large spleen (volume 
above 1,000 ml) was observed in five patients. Only five 
cases (=8 %) had a spleen volume within the normal range 
(140, 180, 200, 200 and 200 ml). When differentiating PV 
from other forms of absolute polycythemia a lower limit 
for "scintigraphic splenomegaly" was defined as the mean 
value - 2 SD in the group of patients with absolute poly­
cythemias other than PV (= 290 ml). Seventeen PV patients 
(= 30 %) had a spleen volume less than 290 ml. 
In nine patients with untreated PV and a slight to mode­
rate splenomegaly the spleen size was determined twice, 
initially at a high Hct level, and later after a subacute 
normalization of the blood volume by repeated phlebotomies. 
The mean value of the spleen scan area at the high Hct 
+ 2 level was 300 - 10 (SEM) cm . After phlebotomy at a nor­
mal Hct level it was 280 - 10 (SEM ) cm^. The difference 
between the mean values was not statistically significant. 
In Paper III spleen size studies were also reported from 
PV patients in relapse and from patients in remission after 
myelosuppressive therapy. In 11 cases with PV in relapse 
the mean value of the spleen scan area was almost identi­
cal to that found in untreated PV. In this group all 
patients had spleens above the normal size. Seventeen pa­
tients studied in remission had a mean value considerably 
lower than in active PV, but still significantly higher 
than in controls. Five patients with PV in remission had 
a spleen of normal size. A group of eight patients was 
studied first before myelosuppressive therapy, and later 
when in remission. In all cases a slight to moderate re­
duction in spleen size occurred, and a statistically signi­
ficant difference was found between the mean values before 
and after therapy. 
Discussion. The aim of our scintigraphic studies was 
to develop a method, that would enable us to separate en­
larged from normal-sized spleens, and to follow changes ir 
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spleen size during different phases of the disease in the 
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same patient. In clinical routine Tc scintigraphy is 
simple and safe for the patient and gives rapid and reliable 
information of the size and location of the spleen. In 
experimental work a high degree of accuracy in the estima­
tion of the actual spleen size is essential. This was 
shown in the investigations reported together with Kutti 
and Weinfeld (1972)and Kutti, Ridell and Weinfeld (1973), 
where access to the present method made it possible to 
correlate the data from quantitative thrombokinetic and 
bone marrow studies to the scintigraphically determined 
spleen size. In the first study a highly significant cor­
relation was shown between the splenic platelet pool (mea­
sured as the recovery of ~*^Cr-labelled platelets) and the 
spleen volume. In the second study significant relation­
ships could be demonstrated between the platelet produc­
tion rate, the body platelet mass and the megakaryocyte 
mass (calculated as megakaryocyte volume/mm whole bone 
marrow) on the one hand, and the spleen volume on the other. 
The normal range for the spleen size in vivo can only 
with difficulty be established from spleen weights found 
in autopsy series, since many spleens undergo rapid changes 
in size immediately before and after death (Ahronheim 1937) . 
However, in two recent studies (Lehti 1971, Myers and Segal 
1974) the spleen weights from cases of sudden traumatic 
death have been reported. In the first study the spleen 
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weight was 142 - 58 g for males, and 127 - 57 g for fema­
les. In the second study the mean weight was 145 g (range 
75 - 245 g) for males, and 115 g (range 55 - 190 g) for 
females. In the present study the mean value for the 
scintigraphically calculated spleen volume in the group of 
control subjects was 140 - 40 ml and the normal range was 
defined as 60 - 220 ml (mean - 2 SD). These figures corre­
spond quite well with the findings in the autopsy series 
related above. They are also in agreement with other 
scintigraphic studies, where the spleen size in normal in­
dividuals was estimated (Holzbach et al. 1962, Larson et 
il. 1970, Sigel et al. 1970). During the passed years we 
lave only encountered two apparently healthy individuals 
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with a spleen volume above the normal range (250 and 260 
ml respectively). Both were tall and heavy young men. 
In PV patients studied at the time of the initial eva­
luation, the size of the spleen is very varying. Most 
cases have a slight to moderate splenomegaly, a few indi­
viduals present a very large spleen, and in a certain pro­
portion of patients, fulfilling other criteria for the 
diagnosis of PV, an enlargement of the spleen cannot be 
demonstrated. In the literature statements regarding the 
percentage of PV patients without splenomegaly are diverg­
ing: 52 % (Videbaek 1950, 48 % (Campbell et al. 1970), 
31 % (Calabresi and Meyer 1959), 25 % (Wasserman and 
Bassen 1959), and 17 % (Perkins et al. 1964). It can be 
supposed that the differences mainly depend on how the 
patients were selected and what type of examination was 
used to detect splenomegaly. In the 325 PVSG patients re­
ported by Berlin (1975) splenomegaly was present in 70 % 
of the cases, but all these were not examined scintigraphi-
cally. In the present series of 57 unselected patients 
with untreated PV, examined with scintigraphy, only five 
(= 8 %) had a normal-sized spleen, while 17 (= 30 %) had 
a very slight increase in spleen size. 
The majority of cases with absolute polycythemias other 
than PV had normal-sized spleens, but in seven patients 
the spleen volume was above the normal range. For the 
differentiation of PV from other forms of absolute poly­
cythemia we consider that the upper range of the spleen 
size for the latter group (mean + 2 SD, 290 ml) should be 
used as a limit (= scintigraphic splenomegaly), rather 
than the upper range for the controls (220 ml). 
The pathogenesis of the splenomegaly in early PV has 
not been sufficiently studied. Some authors assume that 
the enlargement of the spleen is mainly due to engorgement 
with blood (Wintrobe 1967, Weinstein 1973). The results 
from the present study indicate that passive distension of 
the spleen with blood only plays a minor role in producing 
splenic enlargement in early PV. Firstly, no significant 
change in spleen size could be observed, when eight patients 
were examined before and after a marked reduction of the 
circulating blood volume by repeated phlebotomies. Second­
ly, most patient with other absolute polycythemias than PV 
had a great increase of the total blood volume and the RBC 
mass, comparable to what is found in PV, but only a few 
of them had a very slight splenic enlargement. 
If passive engorgement is not responsible for the sple­
nomegaly in PV other causes have to be sought. However, 
Söderström et al. (1975), who recently surveyed the subject, 
concluded by stating that the mechanism of early spleno­
megaly in PV is still obscure. As judged from available 
reports of fine needle punctures of the spleen (Ikkala et 
al. 1967, Berg et al. 1973) myeloid metaplasia seems not 
to be responsible for the splenomegaly in most cases of 
early PV. This is also in accordance with our experience 
in similar cases. Reticuloendothelial cell hyperplasia 
may contribute to the enlargement, but this is not in any 
way proven. In advanced cases of PV on the other hand a 
marked myeloid metaplasia is often present in the grossly 
enlarged spleen (Ward and Block 1971, Silverstein 1974). 
Although a marked splenomegaly in PV often is combined 
with an increased amount of reticulin in the bone marrow 
and myeloid metaplasia, and these features are considered 
to indicate a late stage in the course of the disease 
(Wasserman 1954, Lawrence et al. 1969, Silverstein 1976), 
it has not been demonstrated that also lesser degrees of 
splenomegaly are associated with a less favorable progno­
sis. However, preliminary data from the PVSG suggest that 
early splenomegaly in PV indicates a poorer prognosis for 
survival. In our series of PV certain clinical and labo­
ratory features present at the initial evaluation have 
been compared between patients with normal or slightly 
enlarged spleens (volume <1290 ml; 17 patients) and pati­
ents with scintigraphic splenomegaly (spleen volume 290 
ml; 40 patients) (Table III). A significant difference 
between the two groups was observed for total blood volume, 
RBC mass, serum uric acid and serum vitamin B^ level. 
The groups did not differ in the mean duration of known 
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Table III. Clinical and laboratory findings in 57 patients with un­
treated PV, studied at the time of the initial evaluation. 
The patients have been separated in two groups according 
to the size of the spleen. 
Spleen volume Spleen volume 
<290 ml >290 ml 
n = 17 n = 40 t 
Duration of known months 8 
+ 
10 7 
+ 
10 0. 39 
disease 
Total blood volume 1 5.6 
+ 
0.9 6.7 
+ 
1.1 3, .42* 
Red blood cell ml/kg b.wt. 47 
+ 
10 53 
+ 
12 1, .79* 
mass 
White blood count cells/pl 11.4 + 4.7 12.1 + 7.6 0, .41 
Platelet count eells/pl 431 + 167 381 + 209 0, .87 
LAP score 166 
+ 
81 150 
+ 64 0, .76 
Serum uric acid mg/100 ml 6.0 + 2.0 7.5 + 1.9 2. 47* 
Serum B 12 ng/ml 525 + 130 650 + 350 1, 
*
 
00 00 
The figures denote the mean - 1 SD. 
* indicates a difference between the mean values at the 5 % level. 
disease and neither in the degree of leukocytosis. A corre­
lation between spleen size and white blood count has earli­
er been generally accepted (Lawrence 1955). The observa­
tion time of the patients in this series is still too short 
to allow any conclusions regarding the effect of spleno­
megaly on prognosis for survival. It should, however, be 
noted that of the 12 deaths that so far have occurred ten 
were in the group with large spleens (n = 40), and only 
two in the group with smaller spleens (n = 17). 
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HISTAMINE METABOLISM 
Methods. The histamine metabolism was studied by mea­
surement of histamine in whole blood and the excretion of 
histamine and the two main histamine metabolites, methyl-
histamine (MeHi) and l-methyl-4-imidazoleacetic acid 
(MelmAA) in urine. The histamine content of blood and 
urine was determined by biological assay on isolated 
quinea-pig ileum (Wetterquist and White 1970). MeHi was 
determined spectrophotometrically after reaction with 2,4-
dinitrofluorobenzene (DNFB) (White 1966, Granerus et al. 
1968). MelmAA was measured by thin layer chromatography, 
after esterification with ethanol (Granerus and Magnusson 
1965, Granerus 1968). Urine was collected during two con­
secutive 24 h periods. Blood for the determination of 
histamine was taken in the fasting state in the morning 
following the second day of urine collection. 
Comments on methods. The methods used in this investi­
gation were well established in the laboratory since seve­
ral years. The mean recovery of added internal standards, 
calculated from 20 samples, was for all the substances 
studied in the range of 80 % (histamine 86 - 8 % , MeHi 
77 - 7 % and MelmAA 82 -12 I). The reproducibility of 
the results obtained with the different methods was exami­
ned with duplicate measurements of the same urine sample. 
For histamine the coefficient of variation was 10 %, for 
MeHi 13 % and for MelmAA 8 %. The variability in the 
urinary excretion of histamine, MeHi and MelmAA on two con­
secutive days is reported in Paper IV (histamine 24 %, 
MeHi 17 %, MelmAA 15 %). 
A variety of methods exist for the measurement of hista­
mine in blood and urine. The biological assay, introduced 
by Schultz (1911), was for many years the only available 
method, and this mode of histamine determination is still 
used in many laboratories today. Two chemical methods are 
in use, a spectrophotometric using DNFB (Mclntyre et al. 
1950) and a spectrofluorophotometric using o-phthalaldehyde 
(OPT) (Shore et al. 1959, Oates et al. 1962). Recently 
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an enzymatic isotopic assay, more sensitive and specific 
than the older methods, was described by Beaven et al. 
(1972). The earlier methods all have disadvantages, but 
in trained hands give reproducible results. Results ob­
tained with different methods are, however, difficult to 
compare. Bio-assay of histamine generally seems to give 
slightly lower values than fluorometric determination with 
the OPT method. For this at least two explanations have 
been suggested. Firstly, the OPT method is very sensitive 
for interference from other fluorescing substances, parti­
cularly spermidine, sometimes present in large amounts in 
human tissues (Beaven 1976) . Secondly, the presence of 
smooth muscle inhibitors in human urine may render the 
guinea-pig ileum in the biological assay less sensitive 
to histamine (Wetterquist and White 1970). A further 
source of error when comparing histamine results from 
different studies lies in the fact that the form of hista­
mine on which the values are based is not always reported 
("free base", histamine hydrochloride or acid phosphate). 
Since 60 % of histamine hydrochloride, but only 36 % of 
the acid phosphate is equivalent to the free base (Porter 
and Mitchell 1972), the reported values may differ widely 
depending on the reference used. Methodological differen­
ces of this type may contribute to the considerable varia­
tion among reported normal values for blood and urinary 
histamine (Beall 1965, Porter and Mitchell 1972), and also 
to the discrepancies found in histamine results between 
some clinical studies. 
The urinary excretion of histamine, MeHi and MelmAA is 
influenced by variations both in the intake and in the ab­
sorption of histamine from the food (Mitchell and Code 
1954, Granerus 1968) . Certain common foodstuffs may con­
tain large amounts of histamine and are thereby able to 
cause "spontaneous" fluctuations in the excretion of his­
tamine and its metabolites. A standardized diet with a 
low and constant content of about 300 jag histamine per 
day has been devised by Granerus (1968) and is recommended 
for use in clinical and experimental studies. All patients 
in the present study received this diet, both when hospita-
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lized and as out-patients. Also smoking is known to influ­
ence both the level of blood histamine (Werle and Effkemann 
1940) and the urinary excretion of histamine and histamine 
metabolites (Granerus 1968, Turnbull and Kelvin 1971), but 
during this study all patients were allowed to smoke as 
usual. No predilection for heavy smokers was found among 
the patients with elevated blood histamine values. 
Results. Active PV. The urinary excretion of MeHi and 
MelmAA was significantly higher in patients with active PV 
than in controls. The increase in MelmAA excretion was 
usually slight to moderate. Two patients had values above 
10 mg/24 h, but none showed an increase of the degree found 
in cases with untreated CGL (50-100 mg/24 h). The increase 
in MeHi excretion was in most cases slight, the highest 
observed value being 830 p.g/24 h . The mean blood histamine 
level in patients with untreated PV was more than three 
times higher than in controls. The mean value was still 
higher in patients with PV in relapse. In most cases the 
elevation of the blood histamine level was slight to mode­
rate. One patient had a value of 69.0 pg/100 ml, which is 
more than 15 times the normal, but still far from the values 
encountered in untreated CGL (800-1200 pg/100 ml). All 
patients with active PV had a urinary histamine excretion 
within the normal range. 
PV in remission. Patients with PV in remission had mean 
values for MeHi and MelmAA that did not significantly differ 
from the mean values found in controls. Compared with the 
pre-treatment values available in the same patients all 
remission values of MeHi (with two exceptions) and MelmAA 
were lower, and the difference in the mean values was for 
MelmAA statistically significant. In five of these patients 
the blood histamine level was studied, first at a high Hct 
level, and a second time when in remission after myelo-
suppressive therapy. The mean post-treatment value was 
significantly lower. 
"Spent" polycythemia. Three patients with advanced PV 
(disease duration >120 months) and transformation into 
"spent phase" (Wasserman and Bassen 1959) have been examined. 
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All cases had moderate anemia and leukocytosis between 
20, 000 and 40,000/^.1. The spleen was very large in two 
patients; one patient (F.H.) had undergone splenectomy one 
year earlier (spleen weight 1,800 g). As shown in Table 
IV all patients had a substantial increase in MelmAA excre­
tion. One patient had also a high blood histamine level, 
88.0 pg/100 ml. 
Tab 1 e IV • Blood histamine level and urinary excretion of histamine, 
MeHi and MelmAA in three patients with "spent" polycythemia. 
Patient Age Duration Blood Urinary Urinary Urinary 
no. Sex of known histamine histamine MeHi MelmAA 
disease 
months pg/100 ml /Jg/24 h pg/24 h pg/24 h 
1. M.H. 65 F 140 4.0 11 410 10,900 
2. F.H. 55 M 180 88.0 52 570 12,000 
3. A.J. 75 F 288 11.0 11 - 6,000 
Effect of phlebotomy. Seven patients with untreated PV 
were studied first at a high Hct level and a second time 
after normalization of the blood volume by repeated phle­
botomies. No significant differences were found between 
the two observations for any of the substances studied. 
Further studies of the blood histamine level in diffe­
rent forms of polycythemia. In order to assess the repor­
ted value of blood histamine determination in the clinical 
differentiation of PV from other forms of absolute poly­
cythemia, further patients with high Hct levels have been 
examined. In Fig. 12 are summarized the blood histamine 
values from 17 cases of absolute polycythemia other than 
PV, five cases of pseudopolycythemia, and for comparison 
29 cases of active PV, 11 cases of PV in remission and the 
35 controls, reported in Paper IV. All non-PV patients 
had a blood histamine within the normal range, the highest 
value being 6.3 jug/100 ml. In this material an elevated 
histamine value was thus always synonymous with a diagnosis 
of PV. On the other hand, six of the patients (= 21 %) 
*690 
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Figure 12. Blood hista­
mine level in patients 
with untreated PV, PV 
in remission, other 
forms of absolute poly­
cythemia, pseudopoly-
cythemia and in control 
subject.s. The horizon­
tal lines denote the 
mean values in each 
group. For the controls 
the mean - 2 SD is 
marked. 
with unquestionable active PV had normal blood histamine 
levels. All patients with absolute polycythemias other 
than PV had excretion values of histamine, MeHi and MelmAA 
within the normal range. 
Clinical findings. In untreated PV certain clinical and 
laboratory features were compared between patients with in­
creased and patients with normal histamine formation. A 
urinary MelmAA excretion of 4,100 jag/24 h was used as the 
limit between the groups. The only significant differences 
found between the two groups were in respect to blood baso­
philia and to scintigraphically determined spleen size. 
Larger spleens and a greater number of basophilic leuko­
cytes were found in patients with increased MelmAA excre­
tion. The PV patients were also carefully examined for the 
presence of "histamine-related symptoms". Pruritus was 
found in an equal frequency in the two group: in 8 of 14 
patients with normal and in 11 of 21 patients with elevated 
MelmAA excretion. Also duodenal ulcer occurred with a simi­
lar frequency in the two groups. Pruritus was neither 
correlated to the blood histamine level. None of the pa-
tiens with "spent" polycythemia had pruritus. 
Discussion. Since the basophil leukocyte is the blood 
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cell with the highest histamine content (Graham et al. 
1955), and these cells are increased in number in PV, the 
most natural explanation for the increased histamine forma­
tion in PV is an enlarged•population of basophils. The 
same considerations are relevant for CGL, except that in 
this disease both the degree of basophilia and the increase 
in histamine formation is much more marked. If the life 
time of a histamine-containing basophil leukocyte can be 
estimated to 10 days (Osgood et al. 1954, Berg et al. 1972), 
the basophil "histamine pool" might be calculated to be 
about 50 mg in PV and 500 - 1,000 mg in CGL. Of this hista­
mine only a few per cent are found circulating in the blood, 
in PV about 1 mg (= 2 %). An increased in vitro activity 
of a histamine synthesizing enzyme, leukocyte histidine 
decarboxylase, has been demonstrated in active PV (Krauss 
et al. 1968, Gilbert and Krauss 1970). On the other hand 
Lindell et al. (1961) found that the capacity of the blood 
in PV patients to form histamine was well correlated to the 
number of basophils present. 
Since many of the symptoms characteristic for PV are si­
milar to the biological effects of histamine, some of them, 
particularly pruritus have been connected with an increase 
in blood and urinary histamine (Gilbert et al. 1966). In 
the present material no difference in the occurrence of 
pruritus was found whether the histamine formation was in­
creased or not. Seven patients with untreated PV were 
studied both at a high Hct level and after normalization of 
the blood volume by repeated phlebotomies. In most of the 
patients the pruritus was definitely ameliorated after the 
phlebotomies but no significant difference was found in the 
excretion of histamine metabolites at the two examinations. 
These findings suggest that plethora and capillary disten­
sion of the skin may be a more important cause of itching 
in PV than histamine release. On the other hand quite 
severe pruritus can sometimes be observed in patients with 
"spent" polycythemia and myelofibrosis at normal or low Hct 
values. In untreated CGL the levels of blood histamine 
often exceed 1 mg/100 ml (more than 300 times the normal 
level) but neither pruritus nor other symptoms, that can 
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be referred to "histamine excess" are characteristic for 
this disorder. 
In the present material of untreated PV significant 
correlations was found between the spleen volume, the 
MelmAA excretion and the basophil count. In some large PV 
material (e.g. Lawrence 1955) a correlation has been repor­
ted between spleen size and degree of leukocytosis, but 
this could not be demonstrated in our series of PV patients, 
when spleen size was determined scintigraphically. A 
closer relationship seems to exist between the size of the 
spleen and the proliferation of basophil cells than between 
the spleen size and the total white blood cells. Increased 
histamine formation, enlarged basophil cell pool and sple­
nomegaly may all indicate a more advanced stage of the 
myeloproliferative disorder. 
The value of the comprehensive studies of the histamine 
metabolism as described in this investigation is limited 
in clinical routine and the determinations of histamine 
metabolites in the urine also requires special prescrip­
tions to the patient and are very time-consuming for the 
laboratory. However, the simple determination of blood 
histamine certainly has a place in clinical practice. The 
main indication for its use would be the differentiation 
of PV from other forms of polycythemia. Several studies 
have shown that this test has a good discriminating capa­
city (Brandt et al. 1964, Gilbert et al. 1966). In the 
present series, where histamine was determined with bio-
assay, a certain over-lapping was, however, present. While 
an elevated blood histamine value always meant PV, a normal 
value did not exclude the diagnosis. This type of over­
lapping was also found in the PVSG patients recently re­
ported by Berlin (1975). As suggested by Brandt et al. 
(1964) serial determinations of blood histamine may also 
be helpful in the clinical follow-up of PV patients enter­
ing myelofibrotic or leukemic transformation. 
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DEVELOPMENT OF ACUTE LEUKEMIA 
Among 112 patients with PV observed between January 1971 
and March 197 6 development of AL was observed in eight. 
Totally 29 patients have died, seven of them in AL (= 24 %). 
Several modalities of treatment were used for the patients 
32 in this series (phlebotomy alone, P and alkylating drugs), 
but the groups with different treatment are not homogenous 
enough to be statistically comparable. All the cases who 
developed AL had, however, been treated with alkylating 
drugs, and four of them had obtained chemotherapy alone, 
in absence of radiation. 
The clinical, laboratory, morphologic and cytogenetic 
characteristics of the eight patients who developed AL are 
reported in detail in Paper V. The cytogenetic findings 
have been discussed in an earlier section. No distinctive 
clinical or morphologic findings were present at the time 
of the PV diagnosis, and the leukemic transformation could 
not be predicted in any of the patients. The clinical 
course during the erythrocytotic phase was also uneventful 
in all patients except H.G., who developed a myelofibrosis 
with MM. For the three patients treated with chlorambucil 
alone the total doses varied between 3.6 and 6.4 g over a 
three to six year period. In four patients small to mode-
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rate doses of P had been given initially, before the 
administration of alkylating drugs. 
No distinct transitional or preleukemic phase was obser­
ved in our patients. In Table V the characteristics of the 
transition from PV to AL are presented. In all patients 
except H.G. the interval between the last date when poly­
cythemic blood values (high Hct, sometimes leuko- and 
thrombocytosis) were noted, and the date of the AL diagno­
sis was very short, 0-4 months. This recurrent pattern of 
a very rapid development of AL in seven of our eight pati­
ents does not support the observations in a recent report 
by Meytes et al. (1976) . These authors noted that in their 
patients the development of AL was often preceded by a pre­
leukemic phase of refractory anemia or pancytopenia of 
several months' duration. 
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The interval from PV diagnosis to the development of AL 
was in our patients treated with chlorambucil alone only 
3.5, 4.0 and 5.0 years respectively. This is considerably 
lower than the survival time of PV patients developing AL 
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after P therapy (Osgood 1965, Lawrence et al. 1969), but 
similar to the figures for mean survival in chemotherapy 
treated patients with development of AL reported by Landaw 
(1976) and by the PVSG (Wasserman 1976). 
In spite of our thorough knowledge of the different mani­
festations of the polycythemic disorder, we seem at present 
not to be able to predict the development of AL, neither 
from the findings at the time of the initial evaluation, 
nor from the patient's behaviour during the course of the 
disease. The outstanding common denominator for the pati­
ents who developed AL in the present series was that they 
all were treated with alkylating agents, four of them with 
alkylating agents alone. That this type of therapy, via 
a prolongation of the patient's life should unveil an in­
herent tendency of the disease to spontaneously transform 
into AL is not plausible, since all patients who developed 
AL in our series, had an exceptionally short survival. It 
is more reasonable to assume that patients with PV have an 
increased susceptibility to leukemic transformation, but 
for this to become apparent, it must be provoked by the 
administration of mutagenic drugs or irradiation. On the 
other hand different alkylating agents - as well as irradi­
ation - obviously have a potential to induce a "de novo" 
leukemia, whatever the underlying condition, as has recent­
ly been reported for several non-myeloproliferative and 
even non-malignant disorders (Cardamone et al. 1973, Rosner 
and Grünwald 1974, Rosner and Grünwald 1975, Westberg and 
Swolin 1976) . A direct comparison of the leukemogenic 
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effects of P and alkylating agents in PV has not as yet 
been possible since the latter drugs were introduced for 
32 PV therapy much later than P. Neither does our hetero­
genous material allow such an evaluation of the relative 
risks with the two types of treatment. 
The findings in the present series and the similar expe-
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Table V. Characteristics of the transition between PV and AL. 
Patient Last date Date of Inter­ Features Comments 
no with poly­ AL diag­ val marking the 
cythemic nosis (mo) onset of AL 
blood values (mo/yr) 
(mo/yr) 
1.  S, .G. 12/75 3/76 3 Pancytopenia 
2. M, .B.  5/75 7/75 2 Pancytopenia MM known 
since 1972 
3. W. 1/72 5/72 4 Pancytopenia 
4. H. G. 12/70 8/75 55 Leukocytosis Myelofibro­
with blast sis with MM 
cell increase known since 
1971 
5. H. N. 5/75 5/75 0 Drop in Hct 
6. T. .L. 6/74 8/74 2 Pancytopenia 
7. T. , F.  5/75 6/75 1 Leuko- and 
thrombocytopenia 
8. C. C. 8/71 11/71 3 Pancytopenia 
rience in the more extensive PVSG material (Wasserman 1976) 
indicate that the risks for development of AL after alky­
lating agent therapy in PV are much greater than was ear­
lier thought. In our opinion the use of alkylating agents 
in a treatment programme, where these drugs are administe­
red for remission maintenance, should be seriously recon­
sidered until the long-term results of the randomized 
patients in the PVSG major protocol become more unequivo­
cal. For the present, phlebotomy should be the main thera­
peutic approach for all patients with active PV. When 
serious general symptoms not controllable with phlebotomies, 
excessive thrombocytosis ( > 1, 000 , 000/jul ) or a painful 
splenomegaly necessitates myelosuppressive treatment this 
should be given only as a short course with one of the 
alkylating drugs. For the elderly patient and for those 
patients where a phlebotomy regimen cannot be carefully 
32 
supervised, P is still a good therapeutic alternative. 
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